Mapping p53 mutations in Low-Grade glioma: A voxel-Based neuroimaging analysis

American Journal of Neuroradiology

Volumn 36, Issue 1, 2015, Pages 70-76

  Wang, Y Y ^a,b   Zhang, T ^b   Li, S W ^b   Qian, T Y ^c   Fan, X ^b   Peng, X X ^a   Ma, J ^b   Wang, Lei ^b   Jiang, Tao ^a,b,d  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c SIEMENS LTD   (China)

^d BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BRAIN REGION; FEMALE; GENE MAPPING; GENE MUTATION; GLIOMA; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PREOPERATIVE PERIOD; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SURVIVAL TIME; TEMPORAL LOBE; AGED; BRAIN MAPPING; BRAIN TUMOR; CANCER GRADING; COMPUTER ASSISTED DIAGNOSIS; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROCEDURES; PROGNOSIS;

PROTEIN P53; TP53 PROTEIN, HUMAN;

ADULT; AGED; BRAIN MAPPING; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEUROIMAGING; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84920994808     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A4065     Document Type: Article

References (36)

1. Yang P, Wang Y, Peng X, et al. Management and survival rates in patients with glioma in China (2004 -2010): A retrospective study from a single-institution. J Neurooncol 2013;113:259-66
2. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-73
3. Youland RS, Brown PD, Giannini C, et al. Adult low-grade glioma: 19-year experience at a single institution. Am J Clin Oncol 2013;36:612-19
4. Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: Predictive or prognostic? Clin Cancer Res 2011;17:4588-99
5. Weiler M, Wick W. Molecular predictors of outcome in low-grade glioma. Curr Opin Neurol 2012;25:767-73
6. Bourne TD, Schiff D. Update on molecular findings, management and outcome in low-grade gliomas. Nat Rev Neurol 2010;6:695-701
7. Okamoto Y, Di Patre PL, Burkhard C, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 2004;108:49-56
8. Levidou G, El-Habr E, Saetta AA, et al. P53 immunoexpression as a prognostic marker for human astrocytomas: A meta-analysis and review of the literature. J Neurooncol 2010;100:363-71
9. Cho Y, Gorina S, Jeffrey PD, et al. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994;265:346-55
10. England B, Huang T, Karsy M. Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme. Tumour Biol 2013;34:2063-74
11. Muñoz DM, Tung T, Agnihotri S, et al. Loss of p53 cooperates with K-ras activation to induce glioma formation in a region-independent manner. Glia 2013;61:1862-72
12. Muñoz DM, Guha A. Mouse models to interrogate the implications of the differentiation status in the ontogeny of gliomas. Oncotarget 2011;2:590-98
13. Ständer M, Peraud A, Leroch B, et al. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization grade II astrocytoma or oligoastrocytoma: A long-term analysis. Cancer 2004;101:1028-35
14. Zlatescu MC, TehraniYazdi A, Sasaki H, et al. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 2001;61:6713-15
15. Lai A, Kharbanda S, Pope WB, et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 2011;29:4482-90
16. Ellingson BM, Cloughesy TF, Pope WB, et al. Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: A radiographic study in 358 de novo human glioblastomas. Neuroimage 2012;59:908-16
17. Mueller W, Hartmann C, Hoffmann A, et al. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 2002;161:313-19
18. Wechsler-Reya R, Scott MP. The developmental biology of brain tumors. Annu Rev Neurosci 2001;24:385-428
19. Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N Engl J Med 2005;353:811-22
20. Jacques TS, Swales A, Brzozowski MJ, et al. Combinations of genetic mutations in the adult neural stem cell compartment determine brain tumour phenotypes. EMBO J 2010;29:222-35
21. Simpson JR, Horton J, Scott C, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 1993;26:239-44
22. Barani IJ, Benedict SH, Lin PS. Neural stem cells: Implications for the conventional radiotherapy of central nervous system malignancies. Int J Radiat Oncol Biol Phys 2007;68:324-33
23. Ellingson BM, Lai A, Harris RJ, et al. Probabilistic radiographic atlas of glioblastoma phenotypes. AJNR Am J Neuroradiol 2013;34: 533-40
24. Bates E, Wilson SM, Saygin AP, et al. Voxel-based lesion-symptom mapping. Nat Neurosci 2003;6:448-50
25. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-68
26. Medina J, Kimberg DY, Chatterjee A, et al. Inappropriate usage of the Brunner-Munzel test in recent voxel-based lesion-symptom mapping studies. Neuropsychologia 2010;48:341-43
27. Kimberg DY, Coslett HB, Schwartz MF. Power in voxel-based lesion- symptom mapping. J Cogn Neurosci 2007;19:1067-80
28. Li S, Jiang T, Li G, et al. Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: Preliminary results. Neurol Res 2008;30:567-70
29. Peraud A, Kreth FW, Wiestler OD, et al. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorialWHO grade II astrocytomas and oligoastrocytomas. Clin Cancer Res 2002;8:1117-24
30. Li G, Fang L, Fernandez G, et al. The ventral hippocampus is the embryonic origin for adult neural stem cells in the dentate gyrus. Neuron 2013;78:658-72
31. Zhu Y, Guignard F, Zhao D, et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 2005;8:119-30
32. Sun T, Walsh CA. Molecular approaches to brain asymmetry and handedness. Nat Rev Neurosci 2006;7:655-62
33. Sun T, Patoine C, Abu-Khalil A, et al. Early asymmetry of gene transcription in embryonichumanleft and right cerebral cortex. Science 2005;308:1794-98
34. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002;415:436-42
35. Hsieh A, Ellsworth R, Hsieh D. Hedgehog/GLI1 regulates IGF dependent malignant behaviors in glioma stem cells. J Cell Physiol 2011;226:1118-27
36. Nakagawa Y, Matsumura K, Iwasa M, et al. Single photon emission computed tomography and statistical parametric mapping analysis in cirrhotic patients with and without minimal hepatic encephalopathy. Ann Nucl Med 2004;18:123-29